EUCTR2016-002834-59-ES进行中（未招募）1 期
A double-blind, randomised, placebo-controlled study to assess the effect of SNF472 on progression of cardiovascular calcification on top of standard of care in end-stage-renal-disease (ESRD) patients on haemodialysis (HD)
aboratoris Sanifit0 个研究点目标入组 450 人开始时间: 2016年9月26日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. female or male patients, 18 to 80 years (inclusive) of age at randomisation
- •2. CAC score of 100 to 2000 AU inclusive within a 3-week period prior to randomisation, as measured by a multi-detector CT scanner
- •3. patients who are EITHER = 55 years OR have a history of diabetes mellitus at randomisation
- •4. patients on HD for = 6 months prior to randomisation
- •5. willing and able to understand and sign the informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 270
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 180
排除标准
- •1. scheduled date for kidney transplant from a known living donor
- •2. weight above 300 lbs (136 kg)
- •3. hospitalisation in the previous 3 months prior to randomisation for unstable angina, MI, stroke, transient ischaemic attack, amputation or peripheral or coronary bypass surgery
- •4. history of unstable heart failure in the previous 3 months, defined as an unplanned presentation to a hospital or dialysis treatment facility with signs/symptoms of acute pulmonary edema and requiring ultrafiltration therapy
- •5. history of cancer that has been in remission for < 5 years prior to randomisation. A history of basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin is allowed
- •6. pregnant or trying to become pregnant, currently breast-feeding, or of child-bearing potential (including peri-menopausal women who have had a menstrual period within one year) and not willing to practice birth control using a double barrier method (criteria apply to women only) at least 30 days post last dose of study medication
- •7. hypocalcaemia defined as a serum calcium below 8.0 mg/dL (or 2.0 mmol/L) for the serum calcium most proximal to screening per patient’s medical records
- •8. extreme elevation in serum phosphorous, defined as a phosphorous above 10 mg/dL (or 3.23 mmol/L) within the last 2 months proximal to screening per patient’s medical records
- •9. uncontrolled hypertension defined as any 2 or more consecutive post-dialysis DBP > 100 mmHg within the last 2 months proximal to screening
- •10. expected survival < 2 years in the Investigator’s medical opinion
- •11. known active drug or alcohol abuse within 1 year of randomisation
- •12. use of other investigational drugs within 30 days of randomisation
- •13. non-compliance with dialysis treatment which, in the opinion of the Investigator, evidenced by either repeated missed dialysis treatments or significant non-compliance with the patient’s medication regimen
- •14. Inability to comply with all required study procedures and schedule, inability to speak and read in the protocol-derived language of that patient's clinical site, or unwillingness or inability to give written informed consent
研究者
相似试验
进行中（未招募）
1 期
A double-blind, randomised, placebo-controlled study to evaluate topical 10%phenylephrine gel applied peri-anally in the management of ileal pouch anal anastomosis (IPAA)-related faecal incontinence - A study to Evaluate 10% Phenylephrine Gel in the Management of Faecal IncontinenceIleal pouch anal anastomosis (IPAA)-related faecal incontinenceMedDRA version: 14.1Level: PTClassification code 10016092Term: Faecal incontinenceSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2006-002739-25-GBS.L.A. Pharma (UK) Ltd100
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled study to investigate the tolerability and the effect of three multiple-dose regimens of BIA 9-1067 on the levodopa pharmacokinetics, catechol-0-methyltransferase activity and motor response in parkinson´s disease patients treated with levodopa/dopa-decarboxylaseinhibitorParkinson’s DiseaseMedDRA version: 17.1Level: LLTClassification code 10013113Term: Disease Parkinson'sSystem Organ Class: 100000004852EUCTR2009-012897-12-ROBIAL-Portela & Ca, SA32
尚未招募
3 期
A double-blind, randomised, placebo-controlled study to evaluate the effect of Testofen, a specialized extract of Trigonella foenum-graecum (Fenugreek) seed on sexual function and quality of life (QOL) in healthy females.Female sexual function, energy and staminaMetabolic and Endocrine - Normal metabolism and endocrine development and functionAlternative and Complementary Medicine - Herbal remediesACTRN12611001031954AZPA International80
已完成
不适用
A double-blind, randomised, placebo-controlled study to evaluate the effect of an orally-dosed herbal formulation containing Testofen, on sexual function, performance, and serum testosterone levels in healthy males.Sexual performanceSexual functionAlternative and Complementary Medicine - Herbal remediesMetabolic and Endocrine - Other metabolic disordersACTRN12611000830998AZPA International60
招募中
3 期
A double-blind, randomised, placebo-controlled study to evaluate the effectiveness of an orally dosed supplement, Skin Accumax, containing vitamin A, vitamin E, vitamin C, phosphatidylcholine (lecithin) and diindolylmethane, on treating acne in men and women aged between 16 and 35.AcneACTRN12614000008628Integrated Health Group Pty. Ltd.80